Testing a drug for rare inflammatory diseases
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Eyes & vision, Genetic & congenital, Heart & circulation, Immune system & allergy, Mouth & dental, Skin clinical trials.
This trial is testing a new drug (a JAK inhibitor) for people with rare inflammatory diseases like Behçet's, myositis, or IgG4-related disease that hasn't improved with standard treatments. The goal is to see if it can help control symptoms and reduce inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 64 years old.
- You have one of these rare inflammatory conditions: Behçet's disease, idiopathic inflammatory myopathy (like dermatomyositis or anti-synthetase syndrome), or IgG4-related disease.
- Your disease is active and hasn't gotten better after at least 12 weeks of steroids and at least one other immune-suppressing drug.
- You have not had tuberculosis or have been treated for it and are now clear.
- You are not pregnant or breastfeeding, and do not smoke or have a high risk of heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called nerandomilast in people with active inflammatory muscle disease (myositis) that is not well controlled with current treatments. It aims to see if the drug can improve muscle strength and overall disease activity.
This trial is testing a new investigational drug called IMM0306 for people with IgG4-related disease, a condition where the body's immune system attacks its own organs. If you're currently needing steroids for a flare, this study might offer a new treatment option that could help control the disease with fewer side effects.
This trial tests an investigational drug called AZD5492 for people with active lupus, inflammatory myositis, or rheumatoid arthritis who haven't responded well to other treatments. It aims to see if the drug is safe and how it works in the body.
This trial tests an experimental medicine (BMS-986553) for people with autoimmune diseases that have not improved with other treatments. It aims to see if the drug is safe and helpful for conditions like lupus, myositis, scleroderma, rheumatoid arthritis, and Sjögren's disease.
This trial tests a new treatment called BCT301 for people with IgG4-related disease (an autoimmune condition causing swelling in organs like the pancreas or kidneys) that has not improved with standard treatments. The therapy targets certain immune cells to help reduce disease activity.
This trial tests a drug called sirolimus (which helps calm the immune system) for people with active IgG4-related disease. It may help reduce symptoms like swelling and pain if your current treatments are not working well.
Hear when a new Idiopathic Inflammatory Myopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.